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The last decade has seen transcatheter aortic valve im-
plantation (TAVI) emerge as the standard of care for pa-
tients with severe symptomatic aortic stenosis deemed to be 
either at excessive- or high-risk for surgical aortic valve 
replacement (SAVR). This position is supported by three 
important multicentre randomized trials comparing TAVI to 
the historical gold standard therapies: (1) The Placement of 
AoRTic TraNscathetER Valve Trial Edwards SAPIEN 
Transcatheter Heart Valve (PARTNER) IB Trial compared 
TAVI (Edwards SAPIEN, Edwards Lifesciences Inc., Irvine, 
CA) to optimal medical therapy in patients at excessive sur-
gical risk, and demonstrated an absolute mortality reduction 
of > 20% at 1-year, an effect that was maintained out to 
5-year follow-up;[1] (2) The PARTNER 1A Trial compared 
TAVI (Edwards SAPIEN, Edwards Lifesciences Inc., Irvine, 
CA) and SAVR in patients at high operative risk, and found 
no significant differences in either clinical outcomes or 
valve function at five years;[2] (3) The CoreValve (Core-
Valve, Medtronic Inc., Minneapolis, MN) U.S. Pivotal Trial 
compared TAVI and SAVR, and demonstrated significantly 
reduced mortality among patients treated percutaneously 
(22.2%), compared to those treated with SAVR (28.6%; 
log-rank test P < 0.05) at two years.[3] These strong data 
have resulted in TAVI being used in hundreds of thousands 
of patients worldwide,[4] and incorporated into the guide-
lines for the management of valvular heart disease from 
both the European Society of Cardiology and the American 
Heart Association / American College of Cardiology.[5,6]  
The excellent aforementioned clinical results were 
achieved with first generation TAVI devices, which were 
far from perfect. Important limitations of first generation 
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transcatheter heart valves (THV) included, the requirement 
for large bore vascular access sheaths (18–24 Fr), the inabil-
ity to recapture or reposition the device in case of a subop-
timal implant position, a high requirement for permanent 
pacemaker post-implant, and the relative frequency of mod-
erate aortic paravalvular leak.[7] Thankfully, THV technol-
ogy has not stood still. Relentless device iteration has 
yielded impressive reductions in the size of the required 
delivery system: the Medtronic CoreValve Evolut R in-line 
sheath (Medtronic Inc., Minneapolis, MN) affords delivery 
of 23, 26, and 29 mm THVs via a 14 Fr system.[8] Such de-
velopment has the potential to reduce the incidence of major 
vascular complications and increase the proportion of pa-
tients treated by transfemoral TAVI. Similarly, recapturable, 
repositionable, and retrievable (R3) TAVI systems are 
widely available and add considerably to the safety of the 
procedure.[9–11] Such systems also allow the operator to at-
tempt more challenging anatomy, safe in the knowledge that 
the system can be removed in case of a suboptimal result.  
Post-implantation paravalvular leak (PVL) of moderate 
grade has also been identified as a significant predictor of 
adverse outcome.[12] The aetiology of PVL is multifactorial, 
and has been attributed to suboptimal positioning (THV too 
low or high), insufficient oversizing of the valve relative to 
the surrounding anatomy, and incomplete apposition to the 
contact surface (annulus and leaflets) due to recalcitrant 
calcific deposits. First generation TAVI devices reported  
≥ moderate PVL in up to 20% of cases.[13] The introduction 
of multislice computed tomography (MSCT) for THV siz-
ing was the first important step towards reducing PVL.[14] 
Repositionable TAVI systems and the more recent introduc-
tion of sealing skirts/cuffs/membranes have further reduced 
the incidence of PVL in contemporary practice to approxi-
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mately 3%.[15–18] 
The requirement for permanent pacemaker remains an 
Achilles heel for TAVI. Anchoring the THV and sealing to 
prevent PVL require radial force to be exerted on the sur-
rounding tissues. Such forces can directly or indirectly in-
jure the atrioventricular node or the left bundle branch, due 
to their close association with the aortic valve annulus. The 
rates of new pacemaker and left bundle branch block 
(LBBB) are prosthesis dependent, and are described in up to 
29% of patients.[19] Importantly, the requirement for new 
pacemaker or the development of LBBB has not been asso-
ciated with adverse long-term clinical outcomes, and may 
even provide some protection from sudden death in those 
with pre-existing right bundle branch block.[20,21] With ac-
cumulating experience, there appears to be a less liberal use 
of adjunct pacing: up to 60% of patients with high-degree 
AV block in the early post-implant period, recover normal 
AV conduction within six months.[22] Most importantly, it 
has been recognized that the depth of the THV implant 
within the left ventricular outflow tract (LVOT) is a strong 
independent predictor of disturbance.[23] Hence, clinicians 
tend to implant the prosthesis higher in the LVOT and there 
are on the horizon novel imaging platforms that have the 
potential to reduce implant depth and reduce PPM rates.[24] 
Given the rapid evolution of THV technology, it is not 
surprising that clinicians have continued to apply the tech-
nology to younger and lower-risk patients. The Nordic Aor-
tic Valve Intervention (NOTION) Trial randomized 280 
all-comer patients > 70 years old to TAVI or SAVR, and 
found no difference in the composite primary endpoint of 
death from any cause, stroke, or myocardial infarction at 
one year.[25] Two further randomized trials are comparing 
TAVI to SAVR in intermediate-risk patients (SURTAVI: 
NCT01586910; PARTNER II: NCT01314313). Although 
there is currently a paucity of randomized data definitively 
confirming efficacy in these patients, there is an ever-accu-
mulating non-randomized evidence-base for this indication 
expansion.[26,27] TAVI technology has also been successfully 
expanded to a variety of other clinical situations, including 
treatment of degenerative surgical aortic and mitral pros-
theses,[28] bicuspid aortic valve stenosis,[29] and pure aortic 
incompetence.[30]  
Foremost among the final hurdles for the widespread ap-
plication to all patients with aortic stenosis, is the demon-
stration of long-term durability. A variety of THV valve 
failure modes have been described, including those similar 
to surgical bioprosthetic failure, and novel failure methods 
unique to THVs.[31] To date, significant durability concerns 
have not arisen: in the PARTNER 1 trials, there were no 
reported cases of THV failure at five years.[2] Indeed, the 
longest available follow-up of a THV now stands at 10 
years, and reveals no evidence of valve dysfunction![31] One 
subject of considerable interest in the TAVI field is the re-
cent description of bioprosthetic leaflet thrombosis using 
4D-MSCT.[32] It appears that leaflet thrombosis occurs in all 
bioprosthetic valves (surgical and transcatheter), but the 
incidence may be valve specific. Crucially, the reduced 
leaflet motion was not associated with thromboembolic 
events and resolved following a short period of oral antico-
agulation.  
Ultimately, the further expansion of TAVI technology to 
lower risk patients and “off-label” indications is inevitable. 
Accumulating observation evidence supports such expan-
sion, however the continued demonstration of equivalent 
clinical outcomes to SAVR in younger patients and 
long-term valve durability in randomized controlled trials is 
essential.  
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